Assessment of the cost-effectiveness of Australia's risk-sharing agreement for direct-acting antiviral treatments for hepatitis C: a modelling study

BACKGROUND: Hepatitis C elimination may be possible with broad uptake of direct-acting antiviral treatments (DAAs). In 2016 the Australian government committed A$1.2 billion for five years of unlimited DAAs (March 2016 to February 2021) in a risk-sharing agreement with pharmaceutical companies. We a...

Descripción completa

Detalles Bibliográficos
Autores principales: Scott, Dr Nick, Palmer, Ms Anna, Tidhar, Mr Tom, Stoove, Prof Mark, Sacks-Davis, Dr Rachel S., Doyle, A/Prof Joseph S., Pedrana, Dr Alisa J., Thompson, Prof Alexander, Wilson, Prof David P., Hellard, Prof Margaret
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669355/
https://www.ncbi.nlm.nih.gov/pubmed/35024654
http://dx.doi.org/10.1016/j.lanwpc.2021.100316

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669355/
https://www.ncbi.nlm.nih.gov/pubmed/35024654
http://dx.doi.org/10.1016/j.lanwpc.2021.100316

Ejemplares similares